Source: http://ubphj.nuph.edu.ua/article/view/ubphj.17.128
Timestamp: 2019-04-19 00:17:50+00:00

Document:
Topicality. Metabolic syndrome (MS) is an extremely common medical and social problem. However, there is no modern understanding of the MS ethiopathogenetic mechanisms. Debates about MS discuss different versions of the development of this symptom complex, when each of the clusters can be primary in the pathogenesis of MS. Therefore, any metabolic processes disorders in the human body are always accompanied with and lead to a changes in quantitative and qualitative microbiocenoses composition, and vice versa, microbiota imbalance may induce the development of pathological states including MS.
Aim. To analyze the published data that concern antimicrobial potential of modern drugs with lipid-lowering properties used in complex therapy of MS.
Materials and methods. Lipid-lowering agents and their direct or indirect antimicrobial effect may cause the microbiota imbalance in the human body. While studying the data, we analyzed antimicrobial potential of modern drugs with lipid-lowering properties used in complex therapy of MS. We studied recent research in the field of microecology and the results of significant effect in normal microflora on metabolic processes.
Results and discussion. According to modern concepts, an important pathogenetic link in the obesity and MS development is the imbalance in normal intestinal microflora. At the same time, lipid-lowering agents can have a direct or indirect antimicrobial effect and, consequently, cause an imbalance of microbiota in the human body. Thereby, it is important for the therapy effectiveness to take into account the significant antimicrobial potential of drugs used in the correction of metabolic disorders.
Conclusions. The future complex antimicrobial properties study of drugs used in the correction of described pathological states has a good perspective.
Sergeev, V. V. (2009). Vrach, 2, 36–41.
Villamor, E., Finan, C. C., Ramirez–Zea, M., Roman, A. V. (2016). Prevalence and sociodemographic correlates of metabolic syndrome in school–aged children and their parents in nine Mesoamerican countries. Public Health Nutrition, 20 (2), 255–265.
Grundy, S. M. (2016). Metabolic syndrome update. Trends in cardiovascular medicine, 26 (4), 364–373.
Roitberg, G. E., Ushakova, T. I., Dorosh, Zh. V. (2004). Kardiologiia, 3, 94–101.
Chazova, I. E., Mychka, V. B. (2008). Metabolicheskii sindrom. Мoscow: Меdia Меdika, 319.
Ginzburg, М. М., Koriukov, N. N. (2002). Ozhirenie. Vliianie na razvitie metabolicheskogo sindroma. Profilaktika i lechenie. Мoscow: Меdpraktika, 23–25.
Ikewaki, K., Tohyama, J. (2004). Dyslipidemia in metabolic syndrome. Nihon rinsho. Japanese journal of clinical medicine, 62 (6), 1099–1103.
Chibisov, S. M., Rapoport, S. I., Kolesnikov, D. B. et al. (2008). Klinicheskaia меditcina, 6, 30–35.
Shenderov, B. A. (2011). Probiotics and functional foods. Food Engineering. [Eds UNESCO–EOLSS Joint Committee], in Encyclopedia of Life Support Systems (EOLSS). Oxford,UK: Developed under the Auspices of the UNESCO, EOLSS Publishers.
Topping, D. L., Clifton, P. M. (2001). Shot–chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiological reviews, 81 (3), 1031–1064.
Parfenov, А. I., Chernin, V. V., Bondarenko, V. M. et al. (2014). Russkii meditcinskii zhurnal, 22 (15), 1088–1092.
Velikaia, M. M., Sheveleva, N. E. (2010). Ukrainskyi biofarmatsevtychnyi zhurnal – Ukrainian biopharmaceutical journal, 4 (9), 6 – 12.
Ghose, T. (2016). Statins in Dyslipidemia: handbook of Lipidology, 105.
Тvorogova, М. G., Samoilenko, Е. Yu., Naumov, V. G. (2008). Laboratornaia meditcina, 9, 7–11.
Baranova, N. А., Kreier, V. G., Osmolovskii, А. А. et al. (2010). Immunopatologiia, allergologiia, infektologiia, 1, 240–240.
Kurmangulov, А. А., Dorodneva, E. F., Isakova, D. N. (2016). Ozhirenie i metabolism, 1, 16–19.
Zakharenko, S. M., Fominykh, Yu. A., Mekhtiev, S. N. (2011). Effektivnaia farmakoterapiia, 7, 14–22.
Wostmann, B. S. (1973). Intestinal bile acids and cholesterol absorption in the germfree rat. J. Nutr., 103 (7), 982– 990.
4. Сергеев, В. В. Метаболический синдром : причины, лечение и профилактика / В. В. Сергеев // Врач. – 2009. – № 2. – С. 36–41.
6. Grundy, S. M. Metabolic syndrome update / S. M. Grundy // Trends in Cardiovascular Medicine. – 2016. – Vol. 26, Issue 4. – P. 364–373.
11. Ройтберг, Г. Е. Роль инсулинорезистентности в диагностике метаболического синдрома / Г. Е. Ройтберг, Т. И. Ушакова, Ж. В. Дорош // Кардиол. – 2004. – № 3. – С. 94–101.
13. Чазова, И. Е. Метаболический синдром / И. Е. Чазова, В. Б. Мычка. – М. : Медиа Медика, 2008. – 319 с.
14. Гинзбург, М. М. Ожирение. Влияние на развитие метаболического синдрома. Профилактика и лечение / М. М. Гинзбург, Н. Н. Корюков. – М. : Медпрактика, 2002. – С. 23–25.
15. Ikewaki, K. Dyslipidemia in metabolic syndrome / K. Ikewaki, J. Tohyama // Nihon Rinsho. Japanese J. of Clinical Medicine. – 2004. – Vol. 62, Issue 6. – P. 1099–1103.
17. Метаболический синдром : больше вопросов, чем ответов / С. М. Чибисов, С. И. Рапопорт, Д. Б. Колесников и др. // Клин. мед. – 2008. – № 6. – С. 30–35.
19. Shenderov, B. A. Probiotics and functional foods. Food Engineering. [Eds UNESCO–EOLSS Joint Committee], in Encyclopedia of Life Support Systems (EOLSS). –Oxford,UK: Developed under the Auspices of the UNESCO, EOLSS Publishers, 2011.
20. Topping, D. L. Shot–chain fatty acids and human colonic function : roles of resistant starch and nonstarch polysaccharides / D. L. Topping, P. M. Clifton // Physiol. Rev. – 2001. – Vol. 81, Issue 3. – P. 1031–1064.
21. Симбионтное пищеварение в свете теории А. М. Уголева о пищеварительно–транспортном конвейере / А. И. Парфенов, В. В. Чернин, В. М. Бондаренко и др. // Русс. мед. журн. – 2014. – Т. 22, № 15. – С. 1088–1092.
24. Великая, М. М. Микробиологические аспекты некоторых эндокринных патологий / М. М. Великая, Н. Е. Шевелева // Укр. біофармац. журн. – 2010. – № 4 (9). – С. 6–12.
25. Ghose, T. Statins in Dyslipidemia : Handbook of Lipidology / T. Ghose. – 2016. – 105 p.
26. Творогова, М. Г. Статины – механизм действия и плейотропные эффекты / М. Г. Творогова, Е. Ю. Самойленко, В. Г. Наумов // Лабораторная медицина. – 2008. – № 9. – С. 7–11.
27. Плеотропный эффект статинов, образуемых мицелиальными грибами / Н. А. Баранова, В. Г. Крейер, А. А. Осмоловский и др. // Иммунопатол., аллергол., инфектол. – 2010. – Т. 1. – С. 240.
34. Курмангулов, А. А. Функциональная активность микробиоты кишечника при метаболическом синдроме / А. А. Курмангулов, Е. Ф. Дороднева, Д. Н. Исакова // Ожирение и метаболизм. – 2016. – № 1. – С. 16–19.
36. Захаренко, С. М. Инфекции, микробиота кишечника человека и метаболический синдром / С. М. Захаренко, Ю. А. Фоминых, С. Н. Мехтиев // Эффективная фармакотерапия. – 2011. – № 7. – С. 14–22.
39. Wostmann, B. S. Intestinal bile acids and cholesterol absorption in the germfree rat / B. S. Wostmann // J. Nutr. – 1973. – Vol. 103, Issue 7. – P. 982– 990.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.